Qiming Capital and Hillhouse Capital have led a US$55 million series C round in Jacobio Pharmaceuticals, a Beijing-based clinical stage biotech company. The latest round of funding also witnessed the participation of new investor, Hong Kong-based Prudence Investment Management, according to company’s announcement on official WeChat account.. Co-founded in 2015 by Wang Yinxiang, who also founded Shenzhen-listed innovative pharmaceutical company Betta Pharmaceutical,  Jacobio pharmaceutical focuses on the research and development in field of cancer, autoimmune and infectious diseases. The company’s most advanced program, JAB-3068, … Qiming, Hillhouse Lead $55M Series C Round In Chinese Biotech Firm Jacobio Pharmaceuticals appeared first on China Money Network.